Back to top
more

BioSpecifics Technologies Corp (BSTC)

(Delayed Data from NSDQ)

$66.72 USD

66.72
62,398

+0.21 (0.32%)

Updated May 3, 2019 04:00 PM ET

After-Market: $66.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Anirudha Bhagat headshot

Check These 7 Top-Ranked Stocks With Solid Net Profit Margins

by Anirudha Bhagat

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for April 15th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Is BioSpecifics Technologies (BSTC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BSTC) Outperforming Other Medical Stocks This Year?

BioSpecifics (BSTC) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yes, You Can Time the Market. Find out How - April 02, 2020

by Zacks Equity Research

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Timing the Market, Is it Possible? - February 26, 2020

by Zacks Equity Research

In the long-run, does consistent market timing really matter to be a successful investor?

When Does Market Timing Actually Work? - February 05, 2020

by Zacks Equity Research

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

How to Time the Markets Like an Investing Pro - January 17, 2020

by Zacks Equity Research

In the long-run, does consistent market timing really matter to be a successful investor?

The Market Timing Secrets No One Talks About - December 24, 2019

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Simple Market Timing Strategies That Work - December 04, 2019

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

The Truth About Market Timing - November 14, 2019

by Zacks Equity Research

In the long-run, does consistent market timing really matter to be a successful investor?

BioSpecifics Technologies (BSTC) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BioSpecifics Technologies (BSTC) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Truth About Market Timing - October 24, 2019

by Zacks Equity Research

In the long-run, does consistent market timing really matter to be a successful investor?

BioSpecifics (BSTC) Upgraded to Buy: Here's Why

by Zacks Equity Research

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

When Does Market Timing Actually Work? - October 03, 2019

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

The Truth About Market Timing - September 13, 2019

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)

by Zacks Equity Research

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Endo International Files BLA for Label Expansion of Xiaflex

by Zacks Equity Research

Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.

Yes, You Can Time the Market. Find out How - August 26, 2019

by Zacks Equity Research

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

BioSpecifics Technologies (BSTC) Tops Q2 Earnings Estimates

by Zacks Equity Research

BioSpecifics (BSTC) delivered earnings and revenue surprises of 20.83% and -1.41%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Simple Market Timing Strategies That Work - August 05, 2019

by Zacks Equity Research

In the long-run, does consistent market timing really matter to be a successful investor?

BioSpecifics Technologies (BSTC) Earnings Expected to Grow: What to Know Ahead of Q2 Release

by Zacks Equity Research

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

by Zacks Equity Research

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

by Zacks Equity Research

Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.